Biobanking: the foundation of personalized medicine

Purpose of review Biobanking has been identified as a key area for development in order to accelerate the discovery and development of new drugs. This review describes the recent advances in the field of biobanking and biospecimen research, with special reference to tumour banks which are the biobanks of primary interest in oncology. Recent findings There is a dramatic deficiency of high-quality, well annotated cancer biospecimens. Biospecimen research is a fast developing field that will improve biobanking methodology and biobanking is becoming more professionally organized with increased attention to quality management. Biobank networks are developing rapidly in order to combine and share resources. Summary Biobanking services must improve rapidly to serve the needs of personalized medicine and biospecimen research should be encouraged and supported at all levels from project funding to publication of results. Biobanks need to be run to high professional standards and the importance of adequate funding, training and certification must be emphasized. The growing presence of national and international biobank networks will allow biobanks to synergize. The development of a biobanking community will facilitate teamwork to overcome common challenges and enhance communication with multiple stakeholder groups.

[1]  J. Baust,et al.  Cryopreservation An emerging paradigm change , 2022 .

[2]  Anne Cambon-Thomsen,et al.  Tracing biological collections: between books and clinical trials. , 2008, JAMA.

[3]  J. Vaught,et al.  International Efforts to Develop Biospecimen Best Practices , 2010, Cancer Epidemiology, Biomarkers & Prevention.

[4]  B. Knoppers,et al.  Trends in ethical and legal frameworks for the use of human biobanks , 2007, European Respiratory Journal.

[5]  M. Hansson,et al.  Ethics and biobanks , 2008, British Journal of Cancer.

[6]  Adrian Png,et al.  Evolutionary concepts in biobanking - the BC BioLibrary , 2009, Journal of Translational Medicine.

[7]  Nathan Blow,et al.  Biobanking: freezer burn , 2009, Nature Methods.

[8]  G. Lauss,et al.  Biobank governance in the post-genomic age. , 2010, Personalized medicine.

[9]  Rebecca O Barnes,et al.  Biospecimen use in cancer research over two decades. , 2010, Biopreservation and Biobanking.

[10]  M. Yuille,et al.  Molecular medicine ireland guidelines for standardized biobanking. , 2010, Biopreservation and biobanking.

[11]  Walter C Bell,et al.  Organizational issues in providing high-quality human tissues and clinical information for the support of biomedical research. , 2010, Methods in molecular biology.

[12]  Michael G. Barnes,et al.  Gene Expression Profiles from Peripheral Blood Mononuclear Cells Are Sensitive to Short Processing Delays. , 2010, Biopreservation and biobanking.

[13]  B. Knoppers,et al.  Population Genomics: The Public Population Project in Genomics (P3G): a proof of concept? , 2008, European Journal of Human Genetics.

[14]  E. Wichmann Need for guidelines for standardized biobanking. , 2010, Biopreservation and biobanking.

[15]  Helen M. Moore,et al.  2009 Biospecimen research network symposium: advancing cancer research through biospecimen science. , 2009, Cancer research.

[16]  Innovation OR Stagnation Challenge and Opportunity on the Critical Path to New Medical Products , 2004 .

[17]  Fay Betsou,et al.  Biobanking for better healthcare , 2008, Molecular oncology.

[18]  Michael Neumaier,et al.  Laboratory management of samples in biobanks: European consensus expert group report. , 2010, Biopreservation and biobanking.

[19]  Jim Vaught,et al.  A review of international biobanks and networks: success factors and key benchmarks. , 2009, Biopreservation and biobanking.

[20]  J. Vaught,et al.  Towards norms for accreditation of biobanks for human health and medical research: compilation of existing guidelines into an ISO certification/accreditation norm‐compatible format , 2007 .

[21]  Thomas Burke,et al.  Human Biospecimen Research: Experimental Protocol and Quality Control Tools , 2009, Cancer Epidemiology Biomarkers & Prevention.

[22]  S. Terry,et al.  What are the biggest challenges and opportunities for biorepositories in the next three to five years? , 2010, Biopreservation and biobanking.

[23]  F. Betsou,et al.  Standard Preanalytical Coding for Biospecimens: Defining the Sample PREanalytical Code , 2010, Cancer Epidemiology, Biomarkers & Prevention.

[24]  D. Larsimont,et al.  The role of the pathologist in tissue banking: European Consensus Expert Group Report , 2010, Virchows Archiv.

[25]  Jan-Eric Litton,et al.  Biobanking for Europe , 2007, Briefings Bioinform..

[26]  R. Dhir,et al.  Timing of consent for the research use of surgically removed tissue , 2009, Cancer.

[27]  Michael Barnes,et al.  What are three actionable strategies to improve quality in biomedical research. , 2010, Biopreservation and biobanking.

[28]  D. Larsimont,et al.  Pathology as the cornerstone of human tissue banking: European consensus expert group report. , 2009, Biopreservation and biobanking.

[29]  K. Zatloukal,et al.  Biobank Governance: Trends and Perspectives , 2007, Pathobiology.

[30]  E. Kay,et al.  Integrating biobanks: addressing the practical and ethical issues to deliver a valuable tool for cancer research , 2010, Nature Reviews Cancer.

[31]  James H. Doroshow,et al.  AACR-FDA-NCI Cancer Biomarkers Collaborative Consensus Report: Advancing the Use of Biomarkers in Cancer Drug Development , 2010, Clinical Cancer Research.

[32]  Biobanks need pharma , 2009, Nature.